CMTM6/PD-L1-targeted AAV promotes anti-tumor immune responses and chemotherapy responsiveness
Chemotherapy is one of the important clinical treatments for malignant tumors, but primary or acquired chemotherapy resistance significantly limits patient benefits. Programmed death ligand 1 (PD-L1) has been reported to be regulated by chemotherapy an…